Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma
Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...
Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...
Zacks.com on MSN12d
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...
BioSpace15h
New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...
Yahoo Finance8d
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron, which developed Eylea in collaboration with Bayer AG, seeks to upgrade the eye medication users to a high-dose version as the drug faces threats from biosimilars and rivals, including ...